Wall Street Zen Downgrades Janux Therapeutics (NASDAQ:JANX) to Sell

Janux Therapeutics (NASDAQ:JANX) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Several other research firms have also weighed in on JANX. UBS Group restated a “buy” rating and set a $57.00 price target on shares of Janux Therapeutics in a research report on Tuesday, December 2nd. Stifel Nicolaus lowered their price objective on shares of Janux Therapeutics from $46.00 to $38.00 and set a “buy” rating on the stock in a research report on Tuesday, December 2nd. Guggenheim dropped their target price on shares of Janux Therapeutics from $72.00 to $68.00 and set a “buy” rating on the stock in a research note on Friday, February 27th. Piper Sandler reduced their target price on shares of Janux Therapeutics from $42.00 to $30.00 and set an “overweight” rating for the company in a research report on Friday, January 16th. Finally, HC Wainwright decreased their price target on shares of Janux Therapeutics from $70.00 to $45.00 and set a “buy” rating for the company in a research note on Tuesday, December 2nd. Eleven analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $56.91.

Janux Therapeutics Trading Down 3.3%

JANX stock opened at $13.18 on Friday. The stock’s fifty day simple moving average is $13.68 and its two-hundred day simple moving average is $19.32. Janux Therapeutics has a 1-year low of $12.12 and a 1-year high of $35.34. The stock has a market cap of $801.74 million, a P/E ratio of -7.20 and a beta of 2.88.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Thursday, February 26th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.14. The business had revenue of $7.88 million for the quarter, compared to analysts’ expectations of $0.08 million. As a group, analysts forecast that Janux Therapeutics will post -1.38 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Janux Therapeutics news, insider Thomas Diraimondo sold 2,505 shares of the company’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $13.73, for a total transaction of $34,393.65. Following the sale, the insider directly owned 124,425 shares of the company’s stock, valued at $1,708,355.25. This represents a 1.97% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Charles M. Winter sold 2,401 shares of the stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $13.73, for a total transaction of $32,965.73. Following the transaction, the insider owned 77,721 shares of the company’s stock, valued at $1,067,109.33. This represents a 3.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 19,033 shares of company stock worth $261,323 in the last quarter. 8.10% of the stock is currently owned by company insiders.

Institutional Trading of Janux Therapeutics

Institutional investors have recently modified their holdings of the business. Squarepoint Ops LLC boosted its holdings in Janux Therapeutics by 230.0% in the 2nd quarter. Squarepoint Ops LLC now owns 189,569 shares of the company’s stock worth $4,379,000 after buying an additional 132,121 shares during the period. Aberdeen Group plc raised its holdings in Janux Therapeutics by 21.1% during the 3rd quarter. Aberdeen Group plc now owns 345,476 shares of the company’s stock valued at $8,443,000 after acquiring an additional 60,188 shares during the period. Geode Capital Management LLC lifted its position in shares of Janux Therapeutics by 15.5% during the second quarter. Geode Capital Management LLC now owns 902,312 shares of the company’s stock worth $20,845,000 after acquiring an additional 121,403 shares in the last quarter. Capital Fund Management S.A. purchased a new stake in shares of Janux Therapeutics during the second quarter worth $757,000. Finally, Congress Asset Management Co. bought a new position in shares of Janux Therapeutics in the third quarter worth $1,363,000. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.